Search Immortality Topics:

Page 50«..1020..49505152..6070..»

Mexico Neurology Procedures Outlook to 2025 – Epidemiology Based models are Used to Estimate & Forecast the Procedure Volumes -…

Posted: February 16, 2020 at 3:48 pm

The "Mexico Neurology Procedures Outlook to 2025 - Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, ICP Procedures and Others." report has been added to's offering.


The publisher's new report, Mexico Neurology Procedures Outlook to 2025, provides key procedures data on the Mexico Neurology Procedures. The report provides procedure volumes within market segments - Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, Neurovascular Embolization Procedures, Neurovascular Coiling Assist Procedures, Neurovascular Accessory Procedures, Intracranial Stenting Procedures, ICP Procedures, Dura Substitute Procedures, Neuromodulation Procedures and Minimally Invasive Neurosurgery Procedures.

The data in the report is derived from dynamic market forecast models. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the procedure volumes.


Mexico Neurology Procedures volumes by segments Hydrocephalus Shunting Procedures, Neurovascular Thrombectomy Procedures, Neurovascular Embolization Procedures, Neurovascular Coiling Assist Procedures, Neurovascular Accessory Procedures, Intracranial Stenting Procedures, ICP Procedures, Dura Substitute Procedures, Neuromodulation Procedures and Minimally Invasive Neurosurgery Procedures.

Projections for each of the market segments. Data is provided from 2015 to 2025.

Develop business and investment strategies by identifying the key market segments expected to register strong growth in the near future.

Develop market-entry and market expansion strategies.

Reasons to buy

Story continues

Develop business and investment strategies by identifying the key market segment expected to register strong growth in the near future.

Develop market-entry and market expansion strategies.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What Is This Report About?

2.2 Neurology Procedures Segmentation

2.3 Definitions of Procedures Covered in the Report

3 Neurology Procedures, Mexico

3.1 Neurology Procedures, Mexico, 2015-2025

3.2 Neurology Procedures, Mexico, 2015-2025

4 Dura Substitute Procedures, Mexico

4.1 Dura Substitute Procedures, Mexico, 2015-2025

5 Hydrocephalus Shunting Procedures, Mexico

5.1 Hydrocephalus Shunting Procedures, Mexico, 2015-2025

5.1.1 Revision Hydrocephalus Shunts Procedures, Mexico, 2015-2025

6 ICP Procedures, Mexico

6.1 ICP Procedures, Mexico, 2015-2025

7 Intracranial Stenting Procedures, Mexico

7.1 Intracranial Stenting Procedures, Mexico, 2015-2025

8 Minimally Invasive Neurosurgery Procedures, Mexico

8.1 Minimally Invasive Neurosurgery Procedures, Mexico, 2015-2025

8.1.1 Minimally Invasive Neurosurgical Devices Procedures, Mexico, 2015-2025

9 Neuromodulation Procedures, Mexico

9.1 Neuromodulation Procedures, Mexico, 2015-2025

10 Neurovascular Accessory Procedures, Mexico

10.1 Neurovascular Accessory Procedures, Mexico, 2015-2025

11 Neurovascular Coiling Assist Procedures, Mexico

11.1 Neurovascular Coiling Assist Procedures, Mexico, 2015-2025

12 Neurovascular Embolization Procedures, Mexico

12.1 Neurovascular Embolization Procedures, Mexico, 2015-2025

12.1.1 Flow Diversion Stent Procedures, Mexico, 2015-2025

13 Neurovascular Thrombectomy Procedures, Mexico

13.1 Neurovascular Thrombectomy Procedures, Mexico, 2015-2025

14 Appendix

For more information about this report visit

View source version on


ResearchAndMarkets.comLaura Wood, Senior Press For E.S.T. Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read the rest here:
Mexico Neurology Procedures Outlook to 2025 - Epidemiology Based models are Used to Estimate & Forecast the Procedure Volumes -...

Recommendation and review posted by G. Smith

Global Neurology Software Market Drivers, Key Players, Regions, Application and Forecast to 2020-2025 – Nyse Nasdaq Live

Posted: February 16, 2020 at 3:48 pm

This study has articulated the Global Neurology Software Market with a detailed view of the Global Neurology Software industry including Global production sales, Global revenue, and CAGR. The report delivers core insights regarding the Neurology Software Market report with an in-depth study of market size, country-level market size, region, segmentation market growth, market share, sales analysis, value chain optimization, market players, the competitive landscape, recent developments, product launches, strategic market growth analysis, trade regulations, opportunities analysis, technological innovations, and area marketplace expanding. Moreover, it critically focuses on the application by analyzing the growth rate and consumption of every individual application.

Key vendor/manufacturers in the market:

The major players covered in Neurology Software are: Epic, Brainlab, healthfusion, Athenahealth, Practice Fusion, Nextgen, Bizmatics, Greenway Health, Allscripts, Kareo, Advanced Data Systems, NueMD, etc.

Request a sample of this report @

The Neurology Software Market report majorly offers an understanding about the major drivers, challenges, restraints, competitive landscape, increasing trends, market dynamics, market size, and market share, development status along with government policy, investment opportunities, and supply chains. It categorizes and analyze the segments regarding type, region, and application. This research report offers an aerial view of the Global Neurology Software Market including market share, price, revenue, growth rate, production by type.

The Global Neurology Software Market landscape and leading manufacturers offers competitive landscape and market development status including the overview of every individual market players. Furthermore, it offers productive data of vendors including the profile, specifications of product, applications, annual performance in the industry, sales, revenue, investments, acquisitions and mergers, market size, market share, and more.

The report also understand the export and import, production, and consumption of every particular region holding highest market share, market size, or CAGR. Furthermore, it provides a an potential insights regarding Porters Five Forces including substitutes, potential entrants, buyers, industry competitors, and suppliers with genuine information for understanding the Global Neurology Software Market.

Browse the complete report @

Global Neurology Software Market By Type:

By Type, Neurology Software market has been segmented into Advanced Neurology EMR Software, Other, etc.

Global Neurology Software Market By Application:

By Application, Neurology Software has been segmented into Hospitals, College & Research Institutes, Other, etc.

Report covers detailed study about the gross margin, production, revenue, the price of the Global Neurology Software Market regarding different regions covered in particular section. It majorly focuses on manufacturing analysis including about the raw materials, cost structure, process, operations, and manufacturing cost strategies. The report introduces the industrial chain analysis, downstream buyers, and raw material sources along with the accurate insights of market dynamics. The Neurology Software Market reports delivers the knowledge about market competition between vendors through regional segmentation of markets in terms of revenue generation potential, business opportunities, demand & supply.

The report concludes with the coverage of data of big companies with information about their sales data, upcoming innovations and development, revenue margins, investments, business models, strategies, and business estimations.

Make an enquiry of this report @

Major Table of Contents

1 Neurology Software Market Overview2 Company Profiles3 Market Competition, by Players4 Market Size by Regions5 North America Neurology Software Revenue by CountriesContinued

About Us:

Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us: Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read the original here:
Global Neurology Software Market Drivers, Key Players, Regions, Application and Forecast to 2020-2025 - Nyse Nasdaq Live

Recommendation and review posted by G. Smith

New migraine medication given the green light – ABC News

Posted: February 16, 2020 at 3:48 pm

Migraines are the second leading cause of disability worldwide, with more than 30 million adults affected. They can be painful, incapacitating and can last up to 72 hours without medication and often require some trial and error before finding the best treatment to control the pain.

Thats why doctors and patients are excited when a new anti-migraine option is available. In this case, it's medicine called Reyvow.

Reyvow is a new prescription medication that was recently approved by the Drug Enforcement Administration and is now available at pharmacies. Its believed to act both centrally and peripherally, (which means it acts on the brain as well as on all the other nerves throughout the body). And its the first medication that has been shown to provide pain freedom from headaches and freedom from associated symptoms like nausea and sensitivity to light and sound.

"Reyvow is a new alternative treatment for acute migraines in patients not responding to medicine who have disabling problems. Having a migraine is like waiting for a hurricane to come and trying to close the windows," Dr. Peter Goadsby, Neurologist and Headache specialist at the University of California San Francisco told ABC news.

The Food and Drug Administration and the DEA have approved Eli Lillys Reyvow (lasmiditan) as the first oral medication of its class to treat acute migraines and bothersome symptoms in adults with or without aura (visual or sensory sensations before a migraine).

"We know that the migraine community is keenly interested in additional treatment options, and we remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine," Dr. Nick Kozauer, acting deputy director of the Division of Neurology Products in the FDAs Center for Drug Evaluation and Research, said in a statement following the FDA's approval.

A migraine is a neurological disease characterized by recurrent attacks of severe headache that can cause intense pain, nausea, vomiting, sensitivity to light and sensitivity to sound.

Although the American Headache Society currently recommends triptans (anti-migraine medicine) for immediate relief in certain patients, a survey of 183 patients from three headache centers showed that 79% of patients were willing to try another acute treatment.

Prior to Reyvow, triptans have been on the market since the early '90s and have accounted for almost 80% of migraine treatments prescribed at office visits. Reyvow is unique because it is a new, fast anti-migraine oral medication that eliminates pain and other symptoms within two hours of treatment, according to the FDA.

There is a need for Reyvow because migraines remain under-recognized and undertreated.

"Results from the OVERCOME study revealed that more than 40% of people who know at least one person with migraine felt that the disease is used as an excuse to avoid family, work, or school commitments, and almost 1 in 3 people believed those with migraine make things more difficult for their co-workers. These findings indicate ripple effects from the lack of understanding and respect for the disability faced by people with migraine," Dr. Eric Pearlman, senior medical director, Eli Lilly, told ABC news.

Another study of 5591 people with migraines found that approximately 40% of people had 1 or more unmet needs.

"Pain relief is not enough. Patients want to get back to their life. They want pain freedom from headaches and no associated symptoms," Pearlman said.

Reyvow is taken as a single dose (50mg, 100mg, or 200mg) with or without food at the onset of migraine. Studies, according to the company, showed that 28-39% of patients achieved fast and complete elimination of migraine pain at two hours compared to 15- 20% with placebo. Among individuals who took these doses, 41-49% of achieved freedom from their most bothersome symptoms.

The Food and Drug Administration headquarters in White Oak, Md.

Unlike triptans, patients who have heart disease, peripheral vascular disease, uncontrolled high blood pressure, or history of stroke can take Reyvow as long as their heart rate and blood pressure are monitored because the drug targets nerves rather than blood vessels. Reyvow activates the (5-HT) 1F receptors that increase serotonin (neurotransmitters) and inhibiting pain pathways although the exact mechanism is unknown.

Side effects of Reyvow include dizziness, sedation, headache, fatigue, nausea, vomiting, muscle weakness and serotonin syndrome. Given the side effects, it is not recommended that individuals on this medicine drive or operate heavy machinery within eight hours of taking the medicine. Also caution is warranted when taken in combination with alcohol or other central nervous system depressants.

While Reyvow is the first of a new class, it contains lasmiditan, which is a controlled substance, and at low doses, can create feelings of relaxation, euphoria and possibly hallucinations. However, Eli Lillys Reyvow received a scheduled V drug rating. Scheduling of drugs refers to the abuse and or dependence potential and accessibility of medications from health care providers. Lower scheduled drugs (I and II) have higher abuse and / or dependence potential and do not allow for prescription refills due to tighter regulations.

Reyvow is approximately $640 for a package of 8 tablets. It is expected to be covered by insurance companies and out-of-pocket cost can vary depending on the insurance type. It is important to note that has a co-pay assistance program on its website.

If you suffer from migraines, it is important to establish a good relationship with your healthcare provider to discuss the effectiveness of your migraine treatment. Talk to your healthcare provider for more information and to see if Reyvow is right for you.

"Have a next best step and a plan B," Goadsby recommends.

Dr. Blair Chance is a resident physician in preventive medicine at the University of South Carolina and member of the ABC News Medical Unit.

See the original post:
New migraine medication given the green light - ABC News

Recommendation and review posted by G. Smith

People with Neurological Disorders Have a Higher Risk of Committing Suicide – DocWire News

Posted: February 16, 2020 at 3:48 pm

Having a diagnosis of a neurological disorder is associated with an increased risk of suicide, according to a recent study published in JAMA.

In this nationwide cohort study, researchers assessed 7,300,395 people 15 years and older living in Denmark from 1980 until 2016. They analyzed medical contact for head injury, stroke, epilepsy, polyneuropathy, diseases of myoneural junction, Parkinson disease, multiple sclerosis, central nervous system infections, meningitis, encephalitis, amyotrophic lateral sclerosis, Huntington disease, dementia, intellectual disability, and other brain diseases from 1977 through 2016.

The studys primary endpoint was defined as death by decide, and the researchers estimated this outcome using Poisson regressions, adjusted for sociodemographics, comorbidity, psychiatric diagnoses, and self-harm.

According to the results of the study, than 7.3 million individuals observed over 161.935,233 person-years, 35,483 died by suicide (median duration of follow-up, 23.6 years; interquartile range, 10.0-37.0 years; mean age, 51.9 years; SD, 17.9 years). Of those, the results showed that 14.7% were diagnosed with a neurological disorder, equivalent to a suicide rate of 44.0 per 100.000 person-years compared with 20.1 per 100,000 person-years among individuals not diagnosed with a neurological disorder.

The researchers observed that people diagnosed with a neurological disorder had an adjusted IRR of 1.8 (95% CI, 1.7 to 1.8) compared with those not diagnosed. The excess adjusted IRRs were 4.9 (95% CI, 3.5 to 6.9) for amyotrophic lateral sclerosis, 4.9 (95% CI, 3.1 to 7.7) for Huntington disease, 2.2 (95% CI, 1.9 to 2.6) for multiple sclerosis, 1.7 (95% CI, 1.6 to 1.7) for head injury, 1.3 (95% CI, 1.2 to 1.3) for stroke, and 1.7 (95% CI, 1.6 to 1.8) for epilepsy.

Moreover, the association varied according to time since diagnosis with an adjusted IRR for 1 to 3 months of 3.1 (95% CI, 2.7 to 3.6) and for 10 or more years, 1.5 (95% CI, 1.4 to 1.6, P<.001). Compared with those who were not diagnosed with a neurological disorder, those with dementia had a lower overall adjusted IRR of 0.8 (95% CI, 0.7 to 0.9), which was elevated during the first month after diagnosis to 3.0 (95% CI, 1.9 to 4.6; P<.001). The absolute risk of suicide for people with Huntington disease was 1.6% (95% CI, 1.0% to 2.5%).

The researchers wrote in conclusion that: In Denmark from 1980 through 2016, there was a significantly higher rate of suicide among those with a diagnosed neurological disorder than persons not diagnosed with a neurological disorder. However, the absolute risk difference was small.

Follow this link:
People with Neurological Disorders Have a Higher Risk of Committing Suicide - DocWire News

Recommendation and review posted by G. Smith

Neurological Biomarkers Market to Witness an Outstanding Growth by2018 2026 – Instant Tech News

Posted: February 16, 2020 at 3:48 pm

Global Neurological Biomarkers Market: Overview

The global neurological biomarkers market is expected to witness a rapid growth with the prevailing neurological disorder cases all over the world. A major percentage of world population is affected by neurological disorders, this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual.

There are different variations of biomarkers in the market on the basis of type, application and end users. Based on application, the global neurological biomarkers market is segmented into Spinal Muscular Atrophy (SMA), Multiple Sclerosis, Depression, Schizophrenia, Huntington disease, Parkinson disease, and Alzheimer disease. With respect to type, biomarkers are classified into Imaging biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, and Genomics Biomarkers. Among these, genomics biomarker is anticipated to hold a larger share in the overall market as compared to the others. On the basis of end users, the neurological biomarkers market is categorized into hospitals and research institutes and diagnostic centers.

The report presented here is a complete evaluation of the global neurological biomarkers market with large focus on market dynamics that also includes the market drivers, restraints, and trends and opportunities. It also offers geographical and other segmentation studies of the market.

Global Neurological Biomarkers Market: Trends and Opportunities

Get Sample Copy of this report at

The market for neurological biomarkers is anticipated to remain active with the urge in research initiatives that are taking place. The demand for validating and identifying biomarkers from large population is huge. The research process is being conducted with the help of this method, thus increasing the expectancy of accelerating the neurological biomarkers market growth in the future years.

With the introduction of new neurological biomarkers, the neuropathologists will have to play a crucial role in selection and characterization of suitable treatment strategies. Furthermore, with the advent of personalized and telehealth medication, single-cell biosensors are emerging. These single-cell biosensors can help to integrate molecular and clinical information on a large scale.

Biomarkers are also used for those patients who suffer from traumatic brain injury, subarachnoid hemorrhage, intracerebral hemorrhage, and acute ischemic stroke. The recovery of such crucial and neurocritical diseases is dependent on the mitigation of the patient. In these kind of situations, there may be a delay in conducting image studies or proper examination of the patient because of the complexities involved. This flaw has promoted the use of biomarkers in the market. As the demand for neurological concern is on the rise, so is the market for neurological biomarkers is also on the rise.

Global Neurological Biomarkers Market: Regional Analysis

The global neurological biomarkers market is classified into the regions of Middle East and Africa, Asia Pacific, Latin America, North America and Europe. . Owing to the presence of many noteworthy players, North America is projected to be witnessing a larger share of the overall market as compared to the other regions. A number of research and development projects are carried out in various areas of North America and academic universities have also received the fund provided by the government in order to undertake research.

Apart from North America, the region anticipated exhibit a faster growth is Asia Pacific. This is because of the large population base, and the increasing incidental rates of neurological abnormalities. Apart from that, factors like rising number if geriatric population and the entry of new players into the market may also add pace to the overall market growth of the Asia Pacific region in the years to come.

Get Discount of this report at

Global Neurological Biomarkers Market: Companies Mentioned

Major companies in the neurological biomarkers market are Athena Diagnostics, Myriad RBM, AbaStar MDx, QIAGEN, and Thermo Fisher Scientific.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information: Tailwinds and headwinds molding the market trajectory Market segments based on products, technology, and applications Prospects of each segment Overall current and possible future size of the market Growth pace of the market Competitive landscape and key players strategies

The main aim of the report is to: Enable key stakeholder in the market bet right on it Understand the opportunities and pitfalls awaiting them Assess the overall growth scope in the near term Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.

Enquiry before buying at

Read this article:
Neurological Biomarkers Market to Witness an Outstanding Growth by2018 2026 - Instant Tech News

Recommendation and review posted by G. Smith

Camila Coelho: Why the fashion influencer hid her epilepsy for so long – CBS News

Posted: February 16, 2020 at 3:48 pm

Fashion entrepreneur Camila Coelho is speaking out about her epilepsy in hopes of changing the stigma around the neurological disorder. Epilepsy, which is characterized by unpredictable seizures, affects nearly 3.4 million people in the U.S. and about 50 million people worldwide.

Coelho, who walks exclusive red carpets and works with major designers, launched her own namesake fashion line last year. She has more than 8.5 million Instagram followers, and has hid her condition until recently.

She was diagnosed when she was 9 years old.

"My hand started closing by itself That's when I fainted and I had my seizure," Coelho told CBS News contributor Dr. Tara Narula. "It was like I went to sleep and the next thing I hear is my mom calling my name, and I couldn't answer her."

"My mom told me, 'Camila no one needs to know this, no one needs to know that you had a seizure or that you have epilepsy,' and I know my mom was trying to protect me," she said. "That was one of the reasons why I never opened up."

Coelho, who grew up in Brazil, started taking medication daily, but has had several seizures since her diagnosis more than two decades ago. She moved to the U.S. as a teenager, but continued to hide her condition as her career took off.

"Sometimes I would feel like people would think I was a little crazy because I had to take this medicine and because I had the seizure like something was wrong with my brain," she said.

Epilepsy is a neurological disorder that causes the brain to produce sudden, abnormal bursts of electrical energy. The resulting seizures could be as subtle as someone staring blankly into space to loss of consciousness, convulsions and, with certain seizures, even death.

Asked what the most difficult part of managing epilepsy has been, she said, "The most difficult time I would say would be now, thinking of having a baby."

A doctor recently told Coelho and her husband, caro, that her seizure medication could increase the risk of an abnormal pregnancy, but also explained she could be at risk by going off the medication.

"If you do have a seizure while you're pregnant you could lose your baby," she said. "So I'm scared."

But for now, Coelho is continuing her medication, exercising regularly and making sure to get enough sleep, as tiredness can trigger a seizure. She also has had to turn down several professional opportunities to make sure she gets enough rest and manages stress.

Coelho hopes sharing her struggles will make an impact.

"I made the decision to talk about it because I really believe that I could help someone. If I help one person, it's already worth it for me," she said.

If you suspect someone is having a seizure, the Epilepsy Foundation says you should remain calm and stay with them, turn the person on their side and put something under their head. Call 911 if the seizure lasts more than five minutes.

See the rest here:
Camila Coelho: Why the fashion influencer hid her epilepsy for so long - CBS News

Recommendation and review posted by G. Smith

Page 50«..1020..49505152..6070..»